INT104634

Context Info Confidence 0.35 First Reported 2002 Last Reported 2006 Negated 0 Speculated 0 Reported most in Abstract Documents 6 Total Number 7 Disease Relevance 1.79 Pain Relevance 6.49

isomerase activity (Hsd3b3) mitochondrion (Hsd3b3) oxidoreductase activity (Hsd3b3) endoplasmic reticulum (Hsd3b3)

Anatomy Link Frequency plasma 2 Hsd3b3 (Mus musculus)

Pain Link Frequency Relevance Heat Restless leg syndrome 6 99.68 fluoxetine 22 97.54 Paracetamol 16 97.52 antagonist 6 96.84 gABA 8 95.68 cytokine 2 94.00 antidepressant 16 92.76 anticonvulsant 14 92.68 tolerance 6 92.56 agonist 8 86.44

Disease Link Frequency Relevance Heat Atherosclerosis 7 99.68 Disease 1 85.72 Pain 1 83.28 Convulsion 6 79.24 Peripheral Arterial Disease 1 78.36 Hepatotoxicity 6 75.00 Depression 8 72.96 Stress 2 70.32 Alcohol Addiction 2 5.00

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

Following the largest ever clinical trials programme in patients with IC, cilostazol, a phosophodiesterase III inhibitor, has been licensed for symptom relief in the UK.

Negative_regulation (inhibitor) of phosophodiesterase III associated with restless leg syndrome

1) Confidence 0.35 Published 2002 Journal Diabetes Obes Metab Section Abstract Doc Link 12180354 Disease Relevance 0.82 Pain Relevance 0.66

In contrast, the effect of fluoxetine was counteracted by inhibition of the neurosteroid biosynthesis using drugs like 5alpha-reductase inhibitor, finasteride; 3beta-hydroxysteroid dehydrogenase inhibitor, trilostane; 3alpha-hydroxysteroid dehydrogenase inhibitor, indomethacin; MDR antagonist, PK 11195; or the GABA(A) receptor antagonist, bicuculline.

Negative_regulation (inhibitor) of 3beta-hydroxysteroid dehydrogenase associated with gaba, antagonist and fluoxetine

2) Confidence 0.09 Published 2004 Journal Brain Res. Section Abstract Doc Link 15364024 Disease Relevance 0.15 Pain Relevance 1.27

Furthermore, inhibition of the endogenous neurosteroid biosynthesis by drugs like 5alpha-reductase inhibitor, finasteride (50 mg/kg, s.c.), 3beta-hydroxysteroid dehydrogenase inhibitor, trilostane (30 mg/kg i.p.) or 3alpha-hydroxysteroid dehydrogenase inhibitor, indomethacin (5 mg/kg, i.p.) and GABA(A) receptor antagonist, bicuculline (1 mg/kg, i.p.) blocked the antidepressant like effect of ethanol.

Negative_regulation (inhibitor) of 3beta-hydroxysteroid dehydrogenase associated with antidepressant, gaba and antagonist

3) Confidence 0.07 Published 2002 Journal Neuropharmacology Section Abstract Doc Link 12527484 Disease Relevance 0.13 Pain Relevance 0.99

Furthermore, inhibition of the endogenous neurosteroid biosynthesis by drugs like 5alpha-reductase inhibitor, finasteride (50 mg/kg, s.c.), 3beta-hydroxysteroid dehydrogenase inhibitor, trilostane (30 mg/kg i.p.) or 3alpha-hydroxysteroid dehydrogenase inhibitor, indomethacin (5 mg/kg, i.p.) and GABA(A) receptor antagonist, bicuculline (1 mg/kg, i.p.) blocked the antidepressant like effect of ethanol.

Negative_regulation (inhibitor) of 3beta-hydroxysteroid dehydrogenase associated with antidepressant, gaba and antagonist

4) Confidence 0.07 Published 2002 Journal Neuropharmacology Section Abstract Doc Link 12527484 Disease Relevance 0.13 Pain Relevance 0.99

In contrast, the effect of fluoxetine was counteracted by inhibition of the neurosteroid biosynthesis using drugs like 5alpha-reductase inhibitor, finasteride; 3beta-hydroxysteroid dehydrogenase inhibitor, trilostane; 3alpha-hydroxysteroid dehydrogenase inhibitor, indomethacin; MDR antagonist, PK 11195; or the GABA(A) receptor antagonist, bicuculline.

Negative_regulation (inhibitor) of 3beta-hydroxysteroid dehydrogenase associated with gaba, antagonist and fluoxetine

5) Confidence 0.07 Published 2004 Journal Brain Res. Section Abstract Doc Link 15364024 Disease Relevance 0.15 Pain Relevance 1.27

Acetaminophen treatment also significantly increased plasminogen activator inhibitor-1 (PAI-1) activity and plasma fibrinogen level, and decreased antithrombin III (AT-III) and protein C activities (P < 0.05).

Negative_regulation (decreased) of AT-III in plasma associated with paracetamol

6) Confidence 0.02 Published 2006 Journal Food Chem. Toxicol. Section Abstract Doc Link 16181716 Disease Relevance 0.21 Pain Relevance 0.67

SAC or SPC intake alleviated AT-III and protein C reduction (P < 0.05); but did not affect PAI-1 activity and plasma fibrinogen level (P > 0.05).

Negative_regulation (reduction) of AT-III in plasma

7) Confidence 0.01 Published 2006 Journal Food Chem. Toxicol. Section Abstract Doc Link 16181716 Disease Relevance 0.20 Pain Relevance 0.65

General Comments

This test has worked.